JPS592280B2 - Reagent for measuring enzyme activity involved in purine metabolism - Google Patents
Reagent for measuring enzyme activity involved in purine metabolismInfo
- Publication number
- JPS592280B2 JPS592280B2 JP241980A JP241980A JPS592280B2 JP S592280 B2 JPS592280 B2 JP S592280B2 JP 241980 A JP241980 A JP 241980A JP 241980 A JP241980 A JP 241980A JP S592280 B2 JPS592280 B2 JP S592280B2
- Authority
- JP
- Japan
- Prior art keywords
- solution
- coloring
- buffer
- peroxidase
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000000694 effects Effects 0.000 title claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 16
- 230000004144 purine metabolism Effects 0.000 title claims description 7
- 102000004190 Enzymes Human genes 0.000 title description 20
- 108090000790 Enzymes Proteins 0.000 title description 20
- 239000000243 solution Substances 0.000 claims description 64
- 238000004040 coloring Methods 0.000 claims description 23
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 14
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 14
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 13
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 102000003992 Peroxidases Human genes 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 239000008267 milk Substances 0.000 claims description 7
- 210000004080 milk Anatomy 0.000 claims description 7
- 235000013336 milk Nutrition 0.000 claims description 7
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 7
- 239000012089 stop solution Substances 0.000 claims description 7
- 239000000725 suspension Substances 0.000 claims description 7
- 229930010555 Inosine Natural products 0.000 claims description 6
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 229960003786 inosine Drugs 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 5
- 102100033220 Xanthine oxidase Human genes 0.000 claims description 5
- 108010093894 Xanthine oxidase Proteins 0.000 claims description 5
- 229960005305 adenosine Drugs 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 230000003647 oxidation Effects 0.000 claims description 5
- 238000007254 oxidation reaction Methods 0.000 claims description 5
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims description 4
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims description 3
- 210000003743 erythrocyte Anatomy 0.000 claims description 3
- 239000006166 lysate Substances 0.000 claims description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 2
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 claims description 2
- GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 claims 2
- HQZPQYUQNKTHRR-UHFFFAOYSA-N 1,3-benzothiazol-2-ylhydrazine;hydrochloride Chemical compound Cl.C1=CC=C2SC(=NN)NC2=C1 HQZPQYUQNKTHRR-UHFFFAOYSA-N 0.000 claims 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims 1
- 101710132584 Peroxidase 3 Proteins 0.000 claims 1
- 239000012531 culture fluid Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000006395 oxidase reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 102100036664 Adenosine deaminase Human genes 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000000691 measurement method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000006171 Britton–Robinson buffer Substances 0.000 description 1
- 229940123748 Catalase inhibitor Drugs 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710154508 Purine nucleoside phosphorylase 1 Proteins 0.000 description 1
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- -1 bilirupine Chemical compound 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- QOSATHPSBFQAML-UHFFFAOYSA-N hydrogen peroxide;hydrate Chemical compound O.OO QOSATHPSBFQAML-UHFFFAOYSA-N 0.000 description 1
- OEZPVSPULCMUQB-VRTOBVRTSA-N hydron;(e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine;chloride Chemical compound Cl.C1=CC=C2S\C(=N\N)N(C)C2=C1 OEZPVSPULCMUQB-VRTOBVRTSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004147 pyrimidine metabolism Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
本発明は血中、赤血球溶血液中、培養液中のプリン代謝
に関与する酵素活性の測定用試薬に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a reagent for measuring enzyme activity involved in purine metabolism in blood, erythrocyte lysate, and culture medium.
プリン代謝はピリミジン代謝とともに核酸代謝の主要な
経路として知られ、アデノインから尿酸に至る代謝経路
などが衆知されている。Purine metabolism is known as a major pathway of nucleic acid metabolism along with pyrimidine metabolism, and the metabolic pathway from adenoine to uric acid is well known.
また、プリン代謝に関与する尿素群としてはアデノシン
からイノシンへの分解を触媒するアデノシンデアミナー
ゼ〔以下ADAと略す〕、イノシンからヒポキサンチン
への分解を触媒するプリンヌクレオシドフオスホリラー
ゼ〔以下PNPと略す〕、およびヒポキサンチンからキ
サンチン、次いで 酸への分解を触媒するキサンチンオ
キシダーゼ〔以下XODと略す〕が知られている。Furthermore, the urea group involved in purine metabolism includes adenosine deaminase (hereinafter referred to as ADA), which catalyzes the decomposition of adenosine to inosine, and purine nucleoside phosphorylase (hereinafter referred to as PNP), which catalyzes the decomposition of inosine to hypoxanthine. , and xanthine oxidase (hereinafter abbreviated as XOD) that catalyzes the decomposition of hypoxanthine to xanthine and then to acid.
しかしながら、今日、プリン代謝に係る上述の各種代謝
産物、酵素群において、日常の臨床検査に利用されてい
るのは、わずかに代謝終末産物の尿酸〔痛風、腎疾患な
どで高値を示す〕のみである。しかし、一方で血中のA
DA活性が癌患、肝疾患で増大するという報告が散見さ
れる。However, today, among the various metabolites and enzyme groups mentioned above related to purine metabolism, only the metabolic end product uric acid (high levels are shown in gout, kidney disease, etc.) is used in daily clinical tests. be. However, on the other hand, blood A
There are reports that DA activity is increased in cancer patients and liver diseases.
そしてこれら酵素の活性測定法としてl)基質の減少を
測定する方法、:I)酵素反応の結果、生成するアンモ
ニアを比色定量するカロリメトリツクまたはスペクトロ
フオトメトリツク法は、Iil)共役酵素としてXOD
を用い、生成する尿酸を293nmにおいて比色定量す
る方法などが知られている。しかし、これらの方法、l
)法では基質として用いるプリン塩基の吸光度が血清成
分の影響を受けやすいこと、11)法では血中アンモニ
アの影響を受けやすく、従つてブランク値が変動するこ
と、とくにカロリメトリツク法では遠沈操作を必要とす
るので操作が煩雑となり、且つ感度も悪いこと、111
)法では尿酸の吸光度(293nm)が血清成分の影響
をうけやすく、また既存の尿酸によりブランク値が変動
することなど幾多の欠点を有し、さらに、可視部領域で
吸光度を測定する簡便な方法も見当らない。他方、血中
のPNP活性については、その測定法に関する報告はと
くに見当らない。Methods for measuring the activity of these enzymes include l) a method for measuring the decrease in substrate; I) a calorimetric or spectrophotometric method for colorimetrically quantifying ammonia produced as a result of an enzymatic reaction; XOD
A method is known in which the uric acid produced is determined colorimetrically at 293 nm. However, these methods, l
) method, the absorbance of the purine base used as a substrate is easily affected by serum components, and (11) method, the absorbance of the purine base used as a substrate is easily affected by blood ammonia, so the blank value fluctuates.Especially in the calorimetric method, centrifugation 111 requires manual operation, which makes the operation complicated and has poor sensitivity.
) method has many drawbacks, such as the absorbance (293 nm) of uric acid being easily influenced by serum components and the blank value fluctuating due to existing uric acid. I can't find it either. On the other hand, with regard to PNP activity in blood, there are no particular reports on the method for measuring it.
そこで、本発明者らはこれら二種の酵素の簡便且つ正確
な活性測定法確立すべく種々検討した結果、ウシミルク
起源XODを反応の最終段階で共役酵素として用い、X
OD反応により生成する過酸化水素をペルオキシダーゼ
〔以下PODと略す〕の存在下、還元型色原体に作用さ
せて有色の酸化生成物とし、これを比色定量する新らし
い酵素活性測定法を見出すことに成功した。Therefore, the present inventors conducted various studies to establish a simple and accurate method for measuring the activity of these two enzymes.
Discovery of a new method for measuring enzyme activity in which hydrogen peroxide produced by the OD reaction acts on a reduced chromogen in the presence of peroxidase (hereinafter abbreviated as POD) to produce a colored oxidation product, which is then colorimetrically quantified. It was very successful.
そして、この測定法に従い、各種疾病の患者血清を用い
、ADAおよびPNP活性を測定したところ、ADA活
性は骨髄性白血病、肝炎で、PNP活性はリンパ性白血
病、肝炎で、それぞれ高値を示した。従つて、これら二
種の酵素の定量は臨床的意義を有し、しかも測定方法が
簡便、且つ正確なので本発明の試薬は日常の臨床検査薬
として有用である。According to this measurement method, ADA and PNP activities were measured using serum from patients with various diseases. ADA activity showed high values in myeloid leukemia and hepatitis, and PNP activity showed high values in lymphocytic leukemia and hepatitis. Therefore, the quantitative determination of these two enzymes has clinical significance, and since the measurement method is simple and accurate, the reagent of the present invention is useful as a daily clinical test agent.
本発明の要旨を反応式で示すと XOD 基質→キサンチン一→尿酸+H2O2 H2O H2O,十還元色式原体コ化生成物+H2Oである。The gist of the present invention is shown by a reaction formula. XOD Substrate → xanthine → uric acid + H2O2 H2O H2O, 10-reduced color formula raw material coification product + H2O.
次に本発明の特徴とするところ、また本願発明の効果が
従来技術では得られなかつた点について述べる。Next, the features of the present invention and the points where the effects of the present invention could not be obtained with the prior art will be described.
従来技術において、ウシミルク起源のXODを基質に作
用せしめて、生成するH2O2を色素系に導くに際して
は、色素が一旦生成しても直ちに分解されて可視部領域
による吸光度の変化をもとめることが出来ないとされて
いた。In the conventional technology, when XOD derived from bovine milk is made to act on a substrate and the generated H2O2 is introduced into the dye system, once the dye is generated, it is immediately decomposed and it is not possible to determine the change in absorbance in the visible region. It was said that
即ち、原理的に論するならば、ウシミルク起源のXOD
による反応の電子伝達の型は2電子還元と1電子還元の
混合型である。この電子還元系の反応ではH2O2の他
に0i(スーパーオキサドアニオン)が生成し、それが
PODとコンパウンド(複合体)を形成しペルオキシダ
ーゼを不活性化する難点があつた。これに対し、本願発
明は0.1〜0.3Mクエン酸溶液または0.1〜0.
2N塩酸溶液を酵素反応停止液として使用することに特
徴があり、これによつて0iを酸性下でH2O2に変換
(不均化反応)することができる。このようにして従来
技術の難点を取り除くことにより、ウシミルク起源のX
ODの使用を可能にした簡便なPNP,ADAの活性測
定試薬である。本発明の試薬は1基質溶液、2酵素液、
3反応停止液、4発色液(a)および5発色液(b)の
組合せからなる。In other words, in principle, XOD derived from bovine milk
The type of electron transfer in the reaction is a mixed type of two-electron reduction and one-electron reduction. This electron reduction reaction has the disadvantage that in addition to H2O2, Oi (superoxide anion) is produced, which forms a compound (complex) with POD and inactivates peroxidase. In contrast, the present invention uses a 0.1-0.3M citric acid solution or a 0.1-0.3M citric acid solution.
The method is characterized in that a 2N hydrochloric acid solution is used as the enzymatic reaction termination solution, thereby allowing Oi to be converted to H2O2 (disproportionation reaction) under acidic conditions. In this way, by removing the drawbacks of the conventional technology, X
This is a simple reagent for measuring the activity of PNP and ADA that allows the use of OD. The reagent of the present invention includes 1 substrate solution, 2 enzyme solutions,
It consists of a combination of 3 reaction stop solutions, 4 color developing solutions (a) and 5 color developing solutions (b).
これらの試薬はそれぞれ別個に調製され、ADAまたは
PNP活性を測定するとき順次混合される。Each of these reagents is prepared separately and mixed sequentially when measuring ADA or PNP activity.
基質は目的とする酵素に対応し、異なる。即ち、ADA
に対しアデノシンが、PNPに対しイノシンが用いられ
る。また、アデ゛ノシン、イノシンの純度は、化学用純
度、望ましくは生化学純度で測定可能である。これらの
基質を溶解する緩衡液としては、各酵素の性質からAD
AおよびPNPのとき、0.05〜0.2M,.pH7
〜8の範囲、好ましくはPH7.5付近がよく、例えば
リン酸緩衝液、ブリツトン・ロピンソン緩衝液などが好
適である。どちらの場合もアジ化ナトリウムの添加はカ
タラーゼ阻害剤あるいは防腐剤として有利である。共役
酵素として用いるPNPおよびXODの使用量は、吸光
度の一定となる最小量が前者1.75mu1後者10m
uであつたことから、それ以上、願わくば5倍以上用い
るのが適当である。Substrates vary depending on the enzyme of interest. That is, A.D.A.
Adenosine is used for PNP, and inosine is used for PNP. Further, the purity of adenosine and inosine can be measured by chemical purity, preferably biochemical purity. As a buffer solution for dissolving these substrates, AD
A and PNP, 0.05-0.2M, . pH7
8, preferably around 7.5, and for example, phosphate buffer, Britton-Lopinson buffer, etc. are suitable. In both cases, the addition of sodium azide is advantageous as a catalase inhibitor or preservative. The minimum amount of PNP and XOD used as the conjugate enzyme is 1.75 mu for the former and 10 mu for the latter to keep the absorbance constant.
Since it was u, it is appropriate to use more than that, preferably 5 times or more.
なお、ウシミルク起源XODの精製方法については、1
.硫安分画だけによる、2.硫安分画後ハイドロキシア
ノマタイトクロマトグラフイ一による、3.硫安分画、
ハイドロキシアパタイトグラフイ一後、セフアデツクス
G2OOによる〔以上BiOchem.BlOphys
.526,328(1978)4,}−1artらの方
法〔BlOchem.J.ll6,85l(1970)
〕などあげられるがいずれの方法に従つて得たXODで
も、純度に関係なく測定できる。For the purification method of bovine milk-derived XOD, see 1.
.. 2. Only by ammonium sulfate fractionation. 3. By ammonium sulfate fractionation followed by hydroxyanomatite chromatography. Ammonium sulfate fraction,
After hydroxyapatite graphing, Sephadex G2OO was used [BiOchem. BlOphys
.. 526, 328 (1978) 4,}-1art et al.'s method [BlOchem. J. ll6,85l (1970)
] etc. However, XOD obtained by any method can be measured regardless of purity.
PNPの純度については20U/SPrOtelnの硫
安懸濁液PH6.Oのもので充分測定可能である。Regarding the purity of PNP, ammonium sulfate suspension of 20 U/SPrOteln PH6. It can be sufficiently measured with O.
また、酵素の反応時間は、試料として血清50u1を用
いて検討した結果、ADA,PNPとも90分まで原点
を通る直線を認めたことから20〜30分が妥当と判断
した。Further, as a result of an investigation using 50 μl of serum as a sample, a straight line passing through the origin up to 90 minutes was observed for both ADA and PNP, and therefore 20 to 30 minutes was judged to be appropriate.
また、直線性を認める最大血清量がそれぞれADAl2
5μJ.PNPl2Oμ2であつたことから血清の使用
量はADA,PNPのとき50μjと定めた。なお、酵
素液は1.5〜4M1硫酸アンモニウム懸濁液または4
0〜6001)グリセリン溶液として保存すると有利で
ある。In addition, the maximum serum volume at which linearity was observed was
5 μJ. Since it was PNPl2Oμ2, the amount of serum used was determined to be 50 μj for ADA and PNP. The enzyme solution is a 1.5-4M ammonium sulfate suspension or a 4M ammonium sulfate suspension.
0-6001) It is advantageous to store it as a glycerin solution.
酵素反応の停止液としては、これを反応液に加えたとき
、PH3〜4に止まるような酸性の溶液、例えば0.1
〜0.3Mのクエン酸溶液、0.05〜0.2Nの塩酸
溶液などが好適である。As a stop solution for the enzyme reaction, an acidic solution that stops at pH 3 to 4 when added to the reaction solution, for example, 0.1
-0.3M citric acid solution, 0.05-0.2N hydrochloric acid solution, etc. are suitable.
また、この場合、0.02〜0.1%安息香酸ナトリウ
ムなどの防腐剤を添加することができる。反応停止後の
発色は各発色液とも10分間の放置で安定化し、その後
40〜90分まで安定である。Also, in this case, a preservative such as 0.02-0.1% sodium benzoate can be added. After the reaction has stopped, the color development of each coloring solution becomes stable after being left for 10 minutes, and remains stable for 40 to 90 minutes thereafter.
発色剤としてはPODの存在下、過酸化水素により酸化
されて有色の酸化生成物を形成する還元型原体であれば
よく、できれば酸化生成物の吸光度が血清成分に影響さ
れない400nm以上を示すものが好ましい。The coloring agent may be a reduced active substance that is oxidized by hydrogen peroxide in the presence of POD to form a colored oxidation product, preferably one that exhibits an absorbance of 400 nm or more that is not affected by serum components. is preferred.
また、各発色剤を溶解する緩衝液としてはPH3〜5の
場合、マクルベイン緩衝液、コハク酸緩衝液などが、P
H5〜8の場合、リン酸緩衝液、ブリツトン・ロピンソ
ン緩衝液などが好適である。In addition, as a buffer solution for dissolving each coloring agent, in the case of pH 3 to 5, McAlvaine buffer, succinate buffer, etc.
In the case of H5-8, phosphate buffer, Britton-Robinson buffer, etc. are suitable.
次に、酸化生成物およびそのPH、吸光度を例示する。
なお、本発明の試薬を用い、各酵素活性を測定する際の
、血清成分の影響を検索したところ、アルブミン20ワ
/mlにより若干の阻害が認められたが、グリコース、
尿酸、ビリルピン、アスコルビン酸などの影響はほとん
ど認められなかつた。Next, oxidation products, their PH, and absorbance are illustrated.
In addition, when we searched for the influence of serum components when measuring each enzyme activity using the reagent of the present invention, some inhibition was observed by albumin 20 W/ml, but glycose,
Almost no effects of uric acid, bilirupine, ascorbic acid, etc. were observed.
また、各酵素活性測定における同時再現性ならひに日差
変動は、これらを変動係数として表わすとき、いずれも
3%以下を示した。次に、本発明試薬の調製法ならびに
血清中M八およびPNP活性測定の実際例を具体的に例
示する。Furthermore, the daily variation in simultaneous reproducibility in each enzyme activity measurement was 3% or less when expressed as a coefficient of variation. Next, practical examples of the preparation method of the reagent of the present invention and the measurement of M8 and PNP activities in serum will be specifically illustrated.
実施例 1
試薬の調製
1基質溶液の調製
1) PNP活性測定用
イノシン117ηおよびアジ化ナトリウム23ηを0.
1M.pH7.5のリン酸緩衝液にとかして全量を35
0m1とする。Example 1 Preparation of reagent 1 Preparation of substrate solution 1) Inosine 117η and sodium azide 23η for PNP activity measurement were mixed at 0.
1M. Dissolve the total volume in pH 7.5 phosphate buffer at 35%
0m1.
2〜8℃で保存。Store at 2-8℃.
11) ADA活性測定用
アデノシン117〜およびアジ化ナトリウム23W9を
0.1M,.pH7.5のリン酸緩衝液にとかして全量
を350mtとする。11) Adenosine 117 for measuring ADA activity and sodium azide 23W9 at 0.1M. Dissolve in pH 7.5 phosphate buffer to make a total volume of 350 mt.
2〜8℃で保存。Store at 2-8℃.
2酵素液の調製
1) PNP活性測定用
1) XOD,lOuを2.3Mの硫酸アンモニウム溶
液100mtに懸濁する。2 Preparation of enzyme solution 1) For PNP activity measurement 1) Suspend XOD, 1Ou in 100 mt of 2.3M ammonium sulfate solution.
2) XOD,lOuを50%グリセリン溶液100d
に溶解する。2) XOD, lOu in 100d of 50% glycerin solution
dissolve in
11) ADA活性測定用
1) PNP,l.75uおよびXOD,lOuを2.
3Mの硫酸アンモニウム溶液100dに懸濁する。11) For ADA activity measurement 1) PNP, l. 75u and XOD, lOu 2.
Suspend in 100 d of 3M ammonium sulfate solution.
2) PNP,.l.75uおよびXOD、40uを5
0%グリセリン溶液100m1に溶解する。2) PNP,. l. 75u and XOD, 40u for 5
Dissolve in 100 ml of 0% glycerin solution.
なお、保存はいずれの場合もO〜4℃で褐色ピンに入れ
行なう。3反応停止液(各酵素共通)
1)クエン酸・l水和物4.29および安息香酸ナトリ
ウム50ηを水にとかして全量を100m1とする。In all cases, the samples were stored in brown pins at 0 to 4°C. 3 Reaction stop solution (common to each enzyme) 1) Dissolve 4.29 ml of citric acid l-hydrate and 50 η of sodium benzoate in water to make a total volume of 100 ml.
2)安息香酸ナトリウム50ワをPH2.Oの塩酸溶液
にとかして全量を100m1とする。2) Add 50 watts of sodium benzoate to pH 2. Dissolve in a hydrochloric acid solution of O to make the total volume 100ml.
4発色液(a声よひ5発色液(b)の調製(各酵素共通
)1)発色液(a):3−メチル−2−ベンゾチアゾリ
ノンーヒドラゾン・塩酸塩9.6m9およびPODl4
OOuを0.2M,pH3.5のマクルベイン緩衝液に
とかして全量を50m1とする。4. Coloring solution (a) 5. Preparation of coloring solution (b) (common to each enzyme) 1) Coloring solution (a): 3-methyl-2-benzothiazolinone-hydrazone hydrochloride 9.6m9 and PODl4
Dissolve OOu in 0.2M, pH 3.5 McElvain buffer to make a total volume of 50ml.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
発色液(b):N,N−ジメチルアニリン0.3m1を
0.2M,pH3.5のマクルベイン緩衝液にとかして
全量を50m1とする。Coloring solution (b): Dissolve 0.3 ml of N,N-dimethylaniline in a 0.2 M, pH 3.5 McLuvain buffer solution to make a total volume of 50 ml.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
2)発色液(a):0−ジアニシジン10.5〜を0.
2M,pH6.5のリン酸緩衝液にとかして全量を50
m1とする。2) Coloring solution (a): 0-dianisidine 10.5 to 0.
Dissolve the total volume in 2M, pH 6.5 phosphate buffer at 50%
Let it be m1.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
発色液(b):POD,2.4OOuを3.2Mの硫酸
アンモニウム溶液50m1に懸濁する。Coloring solution (b): POD, 2.4OOu is suspended in 50ml of 3.2M ammonium sulfate solution.
2〜8℃に保存。Store at 2-8°C.
3)発色液(a):4−アミノアンチピリン8ηおよび
POD,4OOuを0.1M,pH7.4のリン酸緩衝
液にとかして全量を50m1とする。3) Coloring solution (a): 4-aminoantipyrine 8η and POD, 4OOu are dissolved in a 0.1 M, pH 7.4 phosphate buffer solution to make a total volume of 50 ml.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
発色液(b):フエノール20即を0.2M1pH8.
0のリン酸緩衝液にとかして全量を50m1とする。Coloring solution (b): 0.2M of phenol 20%, pH 8.
0 phosphate buffer to make a total volume of 50 ml.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
4)発色液(a):p−メトキシアニリン12m1を0
.2M,pH3.5のマクルベイン緩衝液にとかして全
量を50m1とする。4) Coloring solution (a): 12ml of p-methoxyaniline
.. Dissolve in 2M, pH 3.5 McElvain buffer to make the total volume 50ml.
2〜8℃で褐色ピンに保存。Store in brown pins at 2-8℃.
発色液(b):POD,4OOuを3.2Mの硫酸アン
モニウム溶液50m1に懸濁する。Coloring solution (b): POD, 4OOu is suspended in 50ml of 3.2M ammonium sulfate solution.
2〜8℃に保存。Store at 2-8°C.
実施例 2
PNP活性の定量
実施例1に記載の各調製試薬を用い、次の手順で測定し
た。Example 2 Quantification of PNP activity Using each of the prepared reagents described in Example 1, measurement was performed according to the following procedure.
但し、1基質溶液は1)、2酵素液はI〕の1)、3反
応停止液は1)、4発色液(a)および5発色液(b)
はl)を用いた。11.2m1に2100μ!を加え3
7℃で5分間、ブレインキユベートする。However, 1 substrate solution is 1), 2 enzyme solution is 1) of I], 3 reaction stop solution is 1), 4 color developing solution (a) and 5 color developing solution (b)
1) was used. 2100μ in 11.2m1! Add 3
Brain-cubate at 7°C for 5 minutes.
次に血清50μ2を加え、37℃で30分反応させる。
のち、30.5m11次いで4および5を各1m1加え
、37℃で10分間インキユベートしたあと、波長60
0nmで比色定量する。吸光度からPNP活性への換算
は、あらかじめ作製した検量線から試料の吸光度に相当
する酵素活性(IU/l)を読みとることによりできる
。Next, 50μ2 of serum is added and reacted at 37°C for 30 minutes.
After that, 1 ml each of 4 and 5 was added to 30.5 ml and incubated at 37°C for 10 minutes.
Colorimetrically determined at 0 nm. Conversion from absorbance to PNP activity can be performed by reading the enzyme activity (IU/l) corresponding to the absorbance of the sample from a previously prepared calibration curve.
但し、PNP、1単位は上記反応系で1分間に1μモh
のヒボキナンチンを生成する酵素活性である。ADA活
性の定量実施例1に記載の各調製試薬を用い、次の手順
で測定した。However, one unit of PNP is 1 μmol h per minute in the above reaction system.
This is the enzyme activity that produces hyboquinanthine. Quantification of ADA activity Using each of the prepared reagents described in Example 1, ADA activity was measured according to the following procedure.
但し、1基質溶液11)、2酵素液は11)の1)、3
反応停止液は1)、4発色液(a)および5発色液(b
)は1)を用いた。11.2m1に2100μlを加え
、37℃で5分間ブレインキユベートする。However, 1 substrate solution 11) and 2 enzyme solutions are 1) and 3 of 11).
The reaction stop solution is 1), color developing solution 4 (a) and color developing solution 5 (b).
) used 1). Add 2100 μl to 11.2 ml and brain-incubate at 37° C. for 5 minutes.
次に血清50μ2を加え、37℃で30分反応させる。
のち30.5m11次いで4および5各1m1を加え、
37℃で10分間インキユベートしたあと、波長600
nmで比色定量する。吸光度からADA活性への換算は
、あらかじめ作製した検量線から試料の吸光度に相当す
る酵素活性(U/l)を読みとることによりできる。Next, 50μ2 of serum is added and reacted at 37°C for 30 minutes.
After that, 30.5m11 was added, then 1m1 each of 4 and 5 was added.
After incubating for 10 minutes at 37°C,
Colorimetrically determined in nm. Conversion from absorbance to ADA activity can be performed by reading the enzyme activity (U/l) corresponding to the absorbance of the sample from a previously prepared calibration curve.
Claims (1)
溶液、(2)10〜40mUのウシミルク起源キサンチ
ンキシダーゼの1.5〜4M硫酸アンモニウム懸濁液ま
たは40〜60%グリセリン溶液、(3)0.1〜0.
3Mクエン酸溶液または0.1〜0.2N塩酸溶液であ
る反応停止液、(4)発色液(a)および(5)発色液
(b)の組合せよりなり、ウシミルク起源キサンチンオ
キシダーゼ反応により生成する過酸化水素をペルオキシ
ダーゼの存在下で有色の酸化生成物とし、これを比色定
量することを特徴とする血中、赤血球溶血液中、培養液
中のプリン代謝に関与するプリンヌクレオシドフオスホ
リラーゼ活性の測定用試薬。 2 (1)0.625〜5mMのアデノシンを基質とす
る溶液、(2)10〜40mUのウシミルク起源キサン
チンオキシダーゼおよび1.75〜5mUプリンヌクレ
オシドフオスホリラーゼの1.5〜4M硫酸アンモニウ
ム懸濁液または40〜60%グリセリン溶液、(3)0
.1〜0.3Mクエン酸溶液または0.1〜0.2N塩
酸溶液である反応停止液、(4)発色液(a)および(
5)発色液(b)の組合せよりなり、ウシミルク起源キ
サンチンオキシダーゼ反応により生成する過酸化水素を
ペルオキシダーゼの存在下で有色の酸化生成物とし、こ
れを比色定量することを特徴とする血中、赤血球溶血液
中、培養液中のプリン代謝に関与するアデノシンデアミ
ナーゼ活性の測定用試薬。 3 発色液が0.53〜2.12mM3−メチル−2−
ベンゾチアゾリノン−ヒドラゾン・塩酸塩、2〜8uペ
ルオキシダーゼおよび0.1〜0.3M、pH3〜4の
緩衝液からなる発色液(a)と15.8〜63.2mM
N,N−ジエチルアニリンおよび0.1〜0.3M、p
H3〜4の緩衝液からなる発色液(b)の組合せである
特許請求の範囲第1項、または第2項記載の試薬。 4 発色液が0.410〜1.64mM0−ジアニシジ
ンおよび0.2〜0.4M、pH6〜7の緩衝液からな
る発色液(a)と2〜8uペルオキシダーゼの1.5〜
4M、硫酸アンモニウム懸濁液または40〜60%グリ
セリン溶液である発色液(b)の組合せである特許請求
の範囲第1項または第2項記載の試薬。 5 発色液が0.492〜1.97mM4−アミノアン
チピリン、2〜8uペルオキシダーゼおよび0.1〜0
.3M、pH7〜8の緩衝液からなる発色液(a)と2
.13〜8.52mMフェノールまたは2.13〜8.
52mMp−クロロフェノールおよび0.2〜0.3M
、pH8〜9の緩衝液からなる発色液(b)の組合せで
ある特許請求の範囲第1項、または第2項記載の試薬。 6 発色液が1.95〜7.80mMp−メトキシアニ
リンおよび0.2〜0.3M、pH3〜5の緩衝液から
なる発色液(a)と2〜8uペルオキシダーゼの1.5
〜4M、硫酸アンモニウム懸濁液または40〜60%グ
リセリン溶液である発色液(b)の組み合わせである特
許請求の範囲第1項または第2項記載の試薬。[Claims] 1. (1) 0.625-5mM inosine as a substrate solution, (2) 10-40mU suspension of bovine milk xanthine oxidase in 1.5-4M ammonium sulfate or 40-60% glycerin. solution, (3) 0.1-0.
It consists of a combination of a reaction stop solution, which is a 3M citric acid solution or a 0.1-0.2N hydrochloric acid solution, (4) a coloring solution (a), and (5) a coloring solution (b), and is produced by a xanthine oxidase reaction derived from bovine milk. Purine nucleoside phosphorylase activity involved in purine metabolism in blood, erythrocyte lysate, and culture fluid, characterized by converting hydrogen peroxide into a colored oxidation product in the presence of peroxidase, and quantifying this colorimetrically. Reagent for measurement of. 2 (1) a solution with 0.625-5mM adenosine as a substrate; (2) a 1.5-4M ammonium sulfate suspension of 10-40mU bovine milk-derived xanthine oxidase and 1.75-5mU purine nucleoside phosphorylase; or 40-60% glycerin solution, (3)0
.. A reaction stop solution which is a 1-0.3M citric acid solution or a 0.1-0.2N hydrochloric acid solution, (4) a color developing solution (a) and (
5) Blood comprising a combination of the coloring liquid (b), characterized in that hydrogen peroxide produced by a reaction with xanthine oxidase derived from bovine milk is converted into a colored oxidation product in the presence of peroxidase, and this is colorimetrically quantified; Reagent for measuring adenosine deaminase activity involved in purine metabolism in erythrocyte lysate and culture medium. 3 The coloring solution is 0.53-2.12mM 3-methyl-2-
Coloring solution (a) consisting of benzothiazolinone-hydrazone hydrochloride, 2-8u peroxidase and 0.1-0.3M, pH 3-4 buffer and 15.8-63.2mM
N,N-diethylaniline and 0.1-0.3M, p
The reagent according to claim 1 or 2, which is a combination of a coloring solution (b) consisting of a buffer solution of H3-4. 4 Coloring solution (a) consisting of 0.410-1.64mM 0-dianisidine and 0.2-0.4M, pH 6-7 buffer and 1.5-8u of peroxidase
3. The reagent according to claim 1 or 2, which is a combination of a color developing solution (b) which is a 4M ammonium sulfate suspension or a 40-60% glycerin solution. 5 Coloring solution contains 0.492-1.97mM 4-aminoantipyrine, 2-8u peroxidase and 0.1-0
.. Coloring solution (a) consisting of 3M, pH 7-8 buffer and 2
.. 13-8.52mM phenol or 2.13-8.
52mM p-chlorophenol and 0.2-0.3M
The reagent according to claim 1 or 2, which is a combination of a coloring solution (b) consisting of a buffer solution having a pH of 8 to 9. 6 Coloring solution (a) consisting of 1.95-7.80mM p-methoxyaniline and 0.2-0.3M, pH 3-5 buffer and 1.5% of 2-8u peroxidase
4M, ammonium sulfate suspension or a 40-60% glycerin solution in combination with coloring solution (b).
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP241980A JPS592280B2 (en) | 1980-01-11 | 1980-01-11 | Reagent for measuring enzyme activity involved in purine metabolism |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP241980A JPS592280B2 (en) | 1980-01-11 | 1980-01-11 | Reagent for measuring enzyme activity involved in purine metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5699798A JPS5699798A (en) | 1981-08-11 |
| JPS592280B2 true JPS592280B2 (en) | 1984-01-18 |
Family
ID=11528722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP241980A Expired JPS592280B2 (en) | 1980-01-11 | 1980-01-11 | Reagent for measuring enzyme activity involved in purine metabolism |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS592280B2 (en) |
-
1980
- 1980-01-11 JP JP241980A patent/JPS592280B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5699798A (en) | 1981-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4251629A (en) | Determination of hydrogen peroxide | |
| JPS59132900A (en) | Test system and method for measuring nad(p)h | |
| Kohlbecker et al. | Direct spectrophotometric determination of serum and urinary oxalate with oxalate oxidase | |
| Jelikić-Stankov et al. | Determination of uric acid in human serum by an enzymatic method using N-methyl-N-(4-aminophenyl)-3-methoxyaniline reagent | |
| EP0206316B1 (en) | Method and test composition for determination of hydrogen peroxide | |
| JPS6357040B2 (en) | ||
| EP0178113A1 (en) | Reagent for assaying creatine kinase | |
| Guilbault et al. | Enzymatic, fluorometric assay of alpha-amylase in serum. | |
| JPS592280B2 (en) | Reagent for measuring enzyme activity involved in purine metabolism | |
| JPS60203190A (en) | 1-methylhydantoinase, its production and creatinie measuringmethod and reagent | |
| US3985621A (en) | Stopping agents for enzyme reactions of dehydrogenase systems | |
| JP2994831B2 (en) | Cholesterol assay and reagents | |
| US5250416A (en) | Method for highly sensitive determination of NADH using kinase | |
| JPS6028279B2 (en) | Reagent for measuring enzyme activity involved in purine metabolism | |
| EP0353311A1 (en) | Nucleoside oxidase and analytical method using same | |
| JPS60210998A (en) | Test composition, test kit and method for enzymatical measurement of inorganic phosphate | |
| JP2836218B2 (en) | Adenosine deaminase reagent for differential determination | |
| JPH082316B2 (en) | Adenosine deaminase assay reagent | |
| Bieber | pH stat assay for guanine aminohydrolase | |
| JP2868553B2 (en) | Method for measuring diaphorase activity | |
| JPS62151200A (en) | Reagent for measuring magnesium ion | |
| JPS6030696A (en) | Method and reagent for determination of creatinine and creatine | |
| Smoleński et al. | Determination of AMP in the rat heart using skeletal muscle AMP deaminase | |
| JPH0220297A (en) | Assay of choline esterase activity and assay reagent | |
| JPH0588119B2 (en) |